Cargando…

Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients

BACKGROUND: Bone marrow angiogenesis is increased in multiple myeloma (MM) patients, prompting the rationale for using antiangiogenic drugs in the treatment of these patients. OBJECTIVE: To assess angiogenesis in patients with MM at diagnosis and following treatment with an antiangiogenic drug. PATI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cury, Priscilla Cury de Camargo, Higashi, Fabiana, Zacchi, Flávia Fernandes Silva, Palhares, Renata Bacic, Quero, Adriana Alvares, Dias, Ana Luiza Miranda Silva, Crusoé, Edvan de Queiroz, Hungria, Vania Tietsche de Moraes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Hematologia e Hemoterapia 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248500/ https://www.ncbi.nlm.nih.gov/pubmed/31519532 http://dx.doi.org/10.1016/j.htct.2019.04.006

Ejemplares similares

Multiple myeloma and central nervous system involvement: experience of a Brazilian center
por: Dias, Ana Luiza Miranda Silva, et al.
Publicado: (2018)

Impact of the lactate dehydrogenase in association with the International Staging System prognostic score in multiple myeloma patients treated in real life
por: Viol Ferreira Lopes, Maricy Almeida, et al.
Publicado: (2023)

Outcomes of autologous transplantation for multiple myeloma according to different induction regimens
por: de Queiroz Crusoe, Edvan, et al.
Publicado: (2014)

Bilateral breast plasmacytoma: a clinical case report
por: Fischer, Thais Rodrigues da Cunha, et al.
Publicado: (2016)

Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012
por: Hungria, Vânia Tietsche de Moraes, et al.
Publicado: (2013)

For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission
por: Silva, Luiza Soares Vieira da, et al.
Publicado: (2017)

Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?
por: Crusoe, Edvan de Queiroz, et al.
Publicado: (2016)

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2021)

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
por: Crusoe, Edvan De Queiroz, et al.
Publicado: (2020)

New proteasome inhibitors in the treatment of multiple myeloma
por: Hungria, Vania Tietsche de Moraes, et al.
Publicado: (2019)

Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira – 2022. Part I
por: Maiolino, Angelo, et al.
Publicado: (2022)

CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil
por: Hungria, Vania, et al.
Publicado: (2023)

Serum free light chain assays not total light chain assays are the standard of care to assess Monoclonal Gammopathies
por: Tietsche de Moraes Hungria, Vania, et al.
Publicado: (2016)

Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel – ABHH monoclonal gammopathies committe
por: Hungria, Vania, et al.
Publicado: (2020)

COVID-19 in Multiple Myeloma Patients: Frequencies and Risk Factors for Hospitalization, Ventilatory Support, Intensive Care Admission and Mortality -Cooperative Registry from Grupo Brasileiro De Mieloma Multiplo (GBRAM)
por: Garnica, Marcia, et al.
Publicado: (2021)

Thalidomide inhibits inflammation and angiogenesis in tumor 4T1 growth in mice
por: Souza, Cristina M, et al.
Publicado: (2013)

Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma()
por: Crusoé, Edvan de Queiroz, et al.
Publicado: (2021)

P954: MULTIPLE MYELOMA IN LATIN AMERICA CANCER REGISTRY: THE MYLACRE STUDY
por: Hungria, Vania, et al.
Publicado: (2023)

Vitamin D Status and Its Association with Parathyroid Hormone Concentration in Brazilians
por: Martins, Juliana Sálvio, et al.
Publicado: (2017)

Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells
por: Tamilarasan, KP, et al.
Publicado: (2006)

Thalidomide and its analogues in the treatment of Multiple Myeloma
por: Latif, Tahir, et al.
Publicado: (2012)

Thalidomide—Then and Now: Case Report of a Woman With Thalidomide Embryopathy and Review of Current Thalidomide Uses
por: Malik, Sara, et al.
Publicado: (2021)

Thalidomide for the Treatment of Refractory Multiple Myeloma: Association of Plasma Concentrations of Thalidomide and Angiogenic Growth Factors with Clinical Outcome
por: Kakimoto, Tsunayuki, et al.
Publicado: (2002)

Lambda light chain-induced monoclonal gammopathy of renal significance, manifesting with Fanconi Syndrome and osteomalacia
por: Gutiérrez-Peredo, Gabriel Brayan, et al.
Publicado: (2022)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Adverse Effects of Thalidomide Administration, in Patients with Myeloma Multiplex?
por: Svetlana Balkanov, Krstevska, et al.
Publicado: (2014)

Immunomodulatory effects of thalidomide in an experimental brain death liver donor model
por: Santana, Alexandre Chagas, et al.
Publicado: (2021)

Rethinking thalidomide.
Publicado: (1995)

Thalidomide and neurotrophism
por: Soper, Judith R., et al.
Publicado: (2018)

Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide
por: de Mello, Renan Bernardes, et al.
Publicado: (2019)

Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide
por: Costa, Perpétua do Socorro Silva, et al.
Publicado: (2022)

Reversible Pulmonary Hypertension Related to Thalidomide Treatment for Multiple Myeloma
por: Villa, Antonio, et al.
Publicado: (2011)

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
por: Castro, T.B.M., et al.
Publicado: (2016)

Inhibitory Effects of Arsenic Trioxide and Thalidomide on Angiogenesis and Vascular Endothelial Growth Factor Expression in Leukemia Cells
por: Kian, Mahnaz Mohammadi, et al.
Publicado: (2018)

HIF-1α and HIF-2α induced angiogenesis in gastrointestinal vascular malformation and reversed by thalidomide
por: Feng, Nan, et al.
Publicado: (2016)

Thalidomide in Dermatology: Revisited
por: Hassan, Iffat, et al.
Publicado: (2015)

Death and Rebirth of the Thalidomide Molecule: A Case of Thalidomide-Induced Sensory Neuropathy
por: Kesserwani, Hassan
Publicado: (2021)

Thalidomide Induced Nonspecific Interstitial Pneumonia in Patient with Relapsed Multiple Myeloma
por: Kang, Myung-Hee, et al.
Publicado: (2010)

Acute Pulmonary Toxicity from Thalidomide in a Patient with Multiple Myeloma
por: Khalsa, Satkirin K., et al.
Publicado: (2015)

The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
por: Hashimoto, Shigeo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_p32ot6corkt7j1dpe31amb9qr2